Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 3 - Studien 21 bis 29 von insgesamt 29
- Rekrutierung läuftCOGNITION-GUIDE Genomics guided targeted post-neoadjuvant therapy in patients with early breast cancer- a multicenter, open-label, umbrella phase -II study2020-002606-22 ( EudraCT Number )Indikationen
- Rekrutierung läuftNivolumab in combination with cisplatin and 5-flurouracil as induction therapy in children and adults with EBV-positive nasopharyngeal carcinoma
- Rekrutierung läuft
A Phase 2, Open-Label, Parallel Cohort Study of Subcutaneous Amivantamab in Multiple Regimens in Patients with Advanced or Metastatic Solid Tumors including EGFR-mutated Non-Small Cell Lung Cancer [CR109264]
Molekulare Marker - Rekrutierung läuft
PRODIGE 107- ENGIC 01- COLOSOTO
A single-arm phase II study evaluating 5-fluorouracil plus Panitumumab (anti-EGFR) and Sotorasib (KRAS G12C inhibitor) in first-line treatment of patients non-eligible for a doublet/triplet chemotherapy with advanced unresectable KRAS G12C mutated colorectal adenocarcinoma
- Rekrutierung läuftPhase II trial of Pembrolizumab in COmbination with salvage chemotherapy for first-RElapsed or refractory classical Hodgkin lymphoma
- Rekrutierung läuftA Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Cancer without Active Liver Metastases
- Rekrutierung läuftR-Pola-Glo – A prospective multicenter phase 2 study of the chemotherapy-light combination of intravenous rituximab with the antibody-drug conjugate polatuzumab vedotin and the bispecific antibody glofitamab in previously untreated aggressive B-cell lymphoma patients above 60 years of age ineligible for a fully dosed R-CHOPMolekulare Marker
- Rekrutierung läuft
An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphom
- Rekrutierung läuftA Phase 2, Open-label Study to Evaluate the Efficacy and Safety of Different Sequences of Ciltacabtagene Autoleucel (Cilt-cel), Talquetamab SC in Combination with Daratumumab SC (Tal-D) and Teclistamab SC in combination with Daratumumab SC (Tec-D) Following Induction with Daratumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) in Participants with Standard-risk Newly Diagnose Multiple Myeloma